
Clinical Cancer Research Vol. 11, 6139-6147, September 1, 2005
© 2005 American Association for Cancer Research
Estrogen Receptor
Binds to Peroxisome ProliferatorActivated Receptor Response Element and Negatively Interferes with Peroxisome ProliferatorActivated Receptor
Signaling in Breast Cancer Cells
Daniela Bonofiglio1,
Sabrina Gabriele1,
Saveria Aquila1,
Stefania Catalano1,
Mariaelena Gentile2,
Emilia Middea1,
Francesca Giordano2 and
Sebastiano Andò2,3
Authors' Affiliations: Departments of 1 Pharmaco-Biology and 2 Cell Biology, and 3 Centro Sanitario, University of Calabria, Cosenza, Italy
Requests for reprints: Sebastiano Andò, Department of Cell Biology, University of Calabria, Cosenza 87036, Italy. Phone: 39-0984-496201; Fax: 39-0984-496203; E-mail: sebastiano.ando{at}unical.it.
Purpose: The molecular mechanisms involved in the repressive effects exerted by estrogen receptors (ER) on peroxisome proliferatoractivated receptor (PPAR)
mediated transcriptional activity remain to be elucidated. The aim of the present study was to provide new insight into the crosstalk between ER
and PPAR
pathways in breast cancer cells.
Experimental Design: Using MCF7 and HeLa cells as model systems, we did transient transfections and electrophoretic mobility shift assay and chromatin immunoprecipitation studies to evaluate the ability of ER
to influence PPAR response elementmediated transcription. A possible direct interaction between ER
and PPAR
was ascertained by coimmunoprecipitation assay, whereas their modulatory role in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway was evaluated by determining PI3K activity and AKT phosphorylation. As a biological counterpart, we investigated the growth response to the cognate ligands of both receptors in hormone-dependent MCF7 breast cancer cells.
Results: Our data show for the first time that ER
binds to PPAR response element and represses its transactivation. Moreover, we have documented the physical and functional interactions of ER
and PPAR
, which also involve the p85 regulatory subunit of PI3K. Interestingly, ER
and PPAR
pathways have an opposite effect on the regulation of the PI3K/AKT transduction cascade, explaining, at least in part, the divergent response exerted by the cognate ligands 17ß-estradiol and BRL49653on MCF7 cell proliferation.
Conclusion: ER
physically associates with PPAR
and functionally interferes with PPAR
signaling. This crosstalk could be taken into account in setting new pharmacologic strategies for breast cancer disease.
This article has been cited by other articles:

|
 |

|
 |
 
H. J. Lee, J. Ju, S. Paul, J.-Y. So, A. DeCastro, A. Smolarek, M.-J. Lee, C. S. Yang, H. L. Newmark, and N. Suh
Mixed Tocopherols Prevent Mammary Tumorigenesis by Inhibiting Estrogen Action and Activating PPAR-{gamma}
Clin. Cancer Res.,
June 15, 2009;
15(12):
4242 - 4249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Salazar, T. Kashiwada, P. Krejci, P. Muchowski, D. Donoghue, W. R. Wilcox, and L. M. Thompson
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells
Hum. Mol. Genet.,
June 1, 2009;
18(11):
1951 - 1961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Riggs, Y. Li, and C. M. Klinge
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells
Nucleic Acids Res.,
May 1, 2009;
37(8):
2584 - 2595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yin, H. Yuan, X. Zeng, L. Kopelovich, and R. I. Glazer
Inhibition of Peroxisome Proliferator-Activated Receptor {gamma} Increases Estrogen Receptor-Dependent Tumor Specification
Cancer Res.,
January 15, 2009;
69(2):
687 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Conzen
Minireview: Nuclear Receptors and Breast Cancer
Mol. Endocrinol.,
October 1, 2008;
22(10):
2215 - 2228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-K. Han, H.-S. Lee, H.-M. Yang, J. Hur, S.-I. Jun, J.-Y. Kim, C.-H. Cho, G.-Y. Koh, J. M. Peters, K.-W. Park, et al.
Peroxisome Proliferator-Activated Receptor-{delta} Agonist Enhances Vasculogenesis by Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-Kinase/Akt Pathway
Circulation,
September 2, 2008;
118(10):
1021 - 1033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Bonofiglio, H Qi, S Gabriele, S Catalano, S Aquila, M Belmonte, and S Ando
Peroxisome proliferator-activated receptor {gamma} inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner
Endocr. Relat. Cancer,
June 1, 2008;
15(2):
545 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Teresi, S. M. Planchon, K. A. Waite, and C. Eng
Regulation of the PTEN promoter by statins and SREBP
Hum. Mol. Genet.,
April 1, 2008;
17(7):
919 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Krejci, L. Salazar, H. S. Goodridge, T. A. Kashiwada, M. J. Schibler, P. Jelinkova, L. M. Thompson, and W. R. Wilcox
STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes
J. Cell Sci.,
February 1, 2008;
121(3):
272 - 281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Yee, N. Williams, P. Wen, D. C. Young, J. Lester, M. V. Johnson, W. B. Farrar, M. J. Walker, S. P. Povoski, S. Suster, et al.
Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers
Clin. Cancer Res.,
January 1, 2007;
13(1):
246 - 252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Bonofiglio, S. Aquila, S. Catalano, S. Gabriele, M. Belmonte, E. Middea, H. Qi, C. Morelli, M. Gentile, M. Maggiolini, et al.
Peroxisome Proliferator-Activated Receptor-{gamma} Activates p53 Gene Promoter Binding to the Nuclear Factor-{kappa}B Sequence in Human MCF7 Breast Cancer Cells
Mol. Endocrinol.,
December 1, 2006;
20(12):
3083 - 3092.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Association for Cancer Research.